144
Participants
Start Date
October 21, 2019
Primary Completion Date
August 1, 2024
Study Completion Date
August 1, 2024
HQP1351
HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I
Hydroxyurea or Interferon-based therapy
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
Homoharringtonine
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
Imatinib, Dasatinib or Nilotinib
Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
Peking University People's Hospital, Beijing
Ruijing Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Tongji Hospital medical college Huazhong University of Science and Technology, Wuhan
Union Hospital medical college Huazhong University of Science and Technology, Wuhan
Henan Provincial Oncology Hospital, Zhengzhou
Nanfang hospital of southern medical university, Guangzhou
Sun Yat-sen University Cancer Center, Guangzhou
Shenzhen Second People's Hospital, Shenzhen
The First affiliated hospital of Guangxi Medical University, Nanning
Henan Provincial people's Hospital, Zhengzhou
Zhongnan Hospital of Wuhan University, Wuhan
Xiangya Hospital Central South University, Changsha
Jiangsu Province Hospital, Nanjing
The First Affiliated Hospital of Soochow University, Suzhou
The First affiliated hospital of Nanchang University, Nanchang
First Hospital of Jilin University, Changchun
The Affiliated hospital of Qingdao University, Qingdao
Qilu hospital of Shandong University, Jinan
West China Hospital of Sichuan University, Chengdu
Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine(hematology dept), Hangzhou
The First Affiliated Hospital, Zhejiang University School of Medicine(HSCTdept), Hangzhou
Lead Sponsor
HealthQuest Pharma Inc.
INDUSTRY
Ascentage Pharma Group Inc.
INDUSTRY